



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Ye, *et al.*

Appl. No.: 10/755,854

Filed: January 13, 2004

For: **Eosinophil-Derived Neurotoxin as a
Marker for Ovarian Cancer**

Art Unit: 1642

Examiner: J. Tidwell

Atty. Dkt.: 7570/80962

Response to Restriction Requirement

Commissioner of Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, **MS Amendment**
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

In response to the Office Action dated May 8, 2006, in which the Examiner imposed a restriction requirement on the claims of the above-captioned application, Applicants hereby elect the claims of restriction Group I. This includes linking claims 1-4 and 13 as well as claim 5. It is Applicants' understanding that, upon allowance of the linking claims, the claims in restriction groups II-IV will be rejoined.

This election is made without traverse.

Applicants do not believe that any fees, other than those already provided for herewith, are required for the filing of the present document. Nevertheless, any fees that may be needed may be charged to our Deposit Account No. 06-1135 under Order No. 7570/80962.

If, in the opinion of the Examiner, a phone call would help to expedite the prosecution of this application, the Examiner is invited to call Applicants' undersigned attorney at (202) 419-7013.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By: 

Michael A. Sanzo
Reg. No. 36,912
Attorney for Applicants

Date: June 8, 2006
1801 K St., NW, Suite 401L
Washington, DC 20006
(202) 419-7000